Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487903 · ClinicalTrials.gov registry record · Phase 2
Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems
A Phase 2 study, sponsored by Point Biomedical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00487903 is a Phase 2 study that was terminated before completion, run by Point Biomedical. The registered enrollment target is 40 participants.
The verdict
NCT00487903, a Phase 2 study, was terminated before completion, sponsored by Point Biomedical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further evaluate the safety of PB127.
Interventions
- DRUG PB127 for Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487903
The ClinicalTrials.gov registry entry for NCT00487903 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Point Biomedical, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PB127 for Injectable Suspension is the first listed.
NCT00487903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00487903 about?
NCT00487903 is a clinical study titled "Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems". The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further evaluate the safety of PB127.
What is the current status of trial NCT00487903?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-09. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00487903?
The interventions under investigation include: PB127 for Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT00487903?
This trial is sponsored by Point Biomedical, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.